HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER-2 receptor, used alone or in combination with chemotherapy, has shown significant clinical ...
[5].Eppenberger-Castori S, Dirk Klingbiel, Thomas Ruhstaller, et al. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99 [J]. BMC Cancer, 2020,20...
HER-2 is a tyrosine kinase receptor which is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER-2 receptor, used alone or in combination with chemotherapy, has shown significant clinical benef...
Anti-HER-2 targeted therapy was the standard treatment for HER-2-positive breast cancer. The application of monoclonal antibody, such as trastuzumab, has significant improved the prognosis of HER-2 positive breast cancer patients. Additionally, researches on noval HER-2 targeted drugs including mAbs...
INTERPRETATION: The 70-gene prognosis signature is an independent prognostic indicator that identifies a subgroup of HER-2-positive early breast cancer with a favourable long-term outcome. British Journal of Cancer (2010) 103, 1788 – 1793. doi:10.1038/sj.bjc.6605916 www.bjcancer.com Published ...
Patients with HER-2-positive advanced breast cancer were associated with poor prognosis. Meanwhile, HER-2-targeted therapy has dramatically improved survival and prognosis among breast cancer patients. Over the years, multiple HER-2-targeting drugs stepped into clinical practice, and the targeted agents...
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the herceptin, cyclophosphamide, and epirubicin (HERCULES) trial[J]. J Clin Oncol, 2010, 28: 1473-1480...
[6]Kim MH, Kim GM, Kim JH, Kim JY, Park HS, Park S, Cho YU, Park BW, Kim SI, Sohn J. Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years an...
(Hatada, Takuya)3;Miyoshi, Y (Miyoshi, Yasuo)1.High Ki-67 expression and low progesterone receptor expression could independently lead to a worse prognosis for postmenopausal patients with estrogen receptor-positive and HER2-negative breast cancer[J].Clinical Breast Cancer.2015,Vol.15(No.3):204...
Cancer Management and Research Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab This article was published in the ...